Latest Regulatory Challenges News

MedAdvisor reported a 36% revenue drop in FY25, driven by US health program setbacks, and sold its ANZ business to focus on restructuring its US operations.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

The Star Entertainment Group reported a $471.5 million net loss for FY25, marking a 72% improvement from the prior year but underscored by ongoing regulatory challenges and a complex joint venture exit.

Evolution Energy Minerals has disclosed a default notice from Tanzanian regulators over delayed mining commencement, yet remains confident in retaining its key graphite mining license.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Atlas Arteria reported a 32.9% drop in statutory net profit for H1 2025 due to a new French tax, yet achieved solid toll revenue and EBITDA growth, maintaining its 2025 distribution guidance.

Atlas Arteria reported an 11.4% rise in revenue for the half year ended June 2025, driven by toll growth across its global portfolio. However, net profit fell 32.9% due to a one-off French tax and ongoing challenges in the US.

Medibank Private Limited reported steady revenue growth and stable profit for FY25, while navigating ongoing cybercrime-related expenses and regulatory scrutiny. The insurer also announced increased dividends and outlined strategic investments in health services and digital transformation.